alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 526–550 of 619 studies · free to read (page 22 of 25) · 27,780 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Showing 619 studies tagged classification — clear

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 13,259 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Predicting Prodromal Alzheimer's Disease in Subjects with Mild Cognitive Impairment Using Machine Learning Classification of Multimodal Multicenter Diffusion-Tensor and Magnetic Resonance Imaging Data

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Journal of neuroimaging : official journal of the American Society of Neuroimaging 2015-01-28

Our results suggest that DTI data provide better prediction accuracy than GM volume in predementia AD. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Additive value of early-phase β-Amyloid-PET for the differential diagnosis of non-Alzheimer’s disease dementia

✓ Peer-reviewed alzhub usefulness score 40 out of 100. NeuroImage Clinical 2026-01-01

Neurodegeneration status was correctly identified in 78.8% (119/151) of amyloid-negative patients through visual rating, compared to 67.5% (102/151) using logistic regression. 5 key findings →

Participants: 379 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Diagnosis of Alzheimer’s Disease and Frontotemporal Dementia From Electroencephalography Signals

✓ Peer-reviewed alzhub usefulness score 40 out of 100. IEEE Transactions on Neural Systems and Rehabilitation Engineering 2025-01-01

Alzheimer's disease (AD) and frontotemporal dementia (FTD) are the most burdensome neurodegenerative disorders in older populations as they pose significant challenges because of subtle cognitive decline in the initial stages. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Multi-modal data analysis for early detection of alzheimer’s disease and related dementias

✓ Peer-reviewed alzhub usefulness score 40 out of 100. The Journal of Prevention of Alzheimer s Disease 2025-12-01

Until recently, accurate early detection of clinical symptoms associated with Alzheimer's disease (AD) and related dementias (ADRD) has been difficult. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Artificial Intelligence–Enhanced Multi-Algorithm R Shiny Application for Predictive Modeling and Analytics: Case Study of Alzheimer Disease Diagnostics

✓ Peer-reviewed alzhub usefulness score 40 out of 100. JMIR Aging 2025-11-05

The Neural Network classifier achieved an accuracy of 91% with a 95% CI ranging from 0.79-0.97 and an AUC of 94%, on the test set after identifying the most significant features for AD prediction. 5 key findings →

Participants: 174 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The potential role of machine learning and deep learning in differential diagnosis of Alzheimer’s disease and FTD using imaging biomarkers: A review

✓ Peer-reviewed alzhub usefulness score 40 out of 100. The Neuroradiology Journal 2025-01-09

IntroductionThe prevalence of neurodegenerative diseases has significantly increased, necessitating a deeper understanding of their symptoms, diagnostic processes, and prevention strategies. 2 key findings →

Design: narrative review Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Prediction of Alzheimer's Dementia Using Soft Voting Ensemble Learning with Machine Learning

✓ Peer-reviewed alzhub usefulness score 40 out of 100. IJACI International Journal of Advanced Computing and Informatics 2025-04-16

Alzheimer's dementia (AD) is a degenerative brain disease characterized by a decline in cognitive function and memory. 1 key finding →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Brain PET Imaging: Frontotemporal Dementia

✓ Peer-reviewed alzhub usefulness score 39 out of 100. PET clinics 2023-01-01

Brain PET adds value in diagnosing neurodegenerative disorders, especially frontotemporal dementia (FTD) due to its syndromic presentation that overlaps with a variety of other neurodegenerative and psychiatric disorders. 18F-FDG-PET has improved sensitivity and specificity compared with structural MR imaging, with optimal diagnostic results achieved when both techniques are utilized. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Quantitative Brain Positron Emission Tomography in Female 5XFAD Alzheimer Mice: Pathological Features and Sex-Specific Alterations

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Frontiers in medicine 2021-11-26

Successful back-translating clinical biomarkers and molecular imaging methods of Alzheimer's disease (AD), including positron emission tomography (PET), are very valuable for the evaluation of new therapeutic strategies and increase the quality of preclinical studies. 18 F-Fluorodeoxyglucose (FDG)-PET and 18 F-Florbetaben-PET are clinically established biomarkers capturing two key pathological features of AD. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

EEG coherence reflects regional corpus callosum area in Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Journal of neurology, neurosurgery, and psychiatry 2005-01-01

Region specific correlations between corpus callosum size and EEG coherence suggest that the decline in interhemispheric connectivity in Alzheimer's disease results from a specific loss of cortical association neurones projecting through the corpus callosum. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Incidence of amyloid-related imaging abnormalities and health resource utilization in patients with Alzheimer disease receiving monoclonal antibody treatments: A real-world evidence study

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Journal of managed care & specialty pharmacy 2026-04-01

All recently approved monoclonal antibodies (eg, aducanumab, lecanemab, and donanemab) for Alzheimer disease (AD) were shown to increase the risks of amyloid-related imaging abnormalities (ARIA) in randomized clinical trials, which can include brain swelling or hemorrhage. 4 key findings →

Participants: 240 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Predicting Alzheimer progression using EEG-based digital twins

✓ Peer-reviewed alzhub usefulness score 39 out of 100. npj Digital Medicine 2026-08-03

Early and accurate prognosis of Alzheimer’s disease (AD) remains limited by current biomarkers, which are often invasive, require expensive equipment, or fail to predict individual trajectories of cognitive decline. 2 key findings →

Participants: 459 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

AI-driven magnetoencephalography biomarkers in dementia risk prediction: current evidence, challenges and future perspectives

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Frontiers in Dementia 2026-04-07

Fourteen studies met eligibility criteria, covering populations from healthy controls to individuals with subjective cognitive decline, MCI, AD, and other dementias. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Longitudinal Structural MRI-Based Deep Learning And Radiomics Features For Predicting Alzheimer\\\\\\\'s Disease Progression

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Zenodo (CERN European Organization for Nuclear Research) 2026-01-01

Alzheimer\\\'s disease (AD), the leading cause of dementia worldwide, affects more than 55 million individuals and gen-erates annual healthcare costs exceeding two trillion USD [14]. 5 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Visual Versus Fully Automated Analyses of 18F-FDG and Amyloid PET for Prediction of Dementia Due to Alzheimer Disease in Mild Cognitive Impairment

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2015-11-19

Both (18)F-FDG and (11)C-PiB imaging appear to be of limited use for predicting the progression from MCI to dementia due to AD in short-term follow-up, irrespective of the strategy of analysis. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Long-term impact of disclosing amyloid PET results to individuals with subjective cognitive decline

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Alzheimer s Research & Therapy 2026-03-27

Participants’ motivations for testing and long-term adaptation to the results were strongly shaped by cognitive concerns and personal experiences of dementia in relatives. 5 key findings →

Participants: 17 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Evaluation of AccuBrain-based MRI quantitative analysis in diagnosing Alzheimer’s disease and assessing behavioral and psychological symptoms of dementia

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Aging Clinical and Experimental Research 2025-04-17

AD patients had significantly higher AD-RAI (0.91 ± 0.25) and more pronounced hippocampal atrophy (0.36 ± 0.09) compared to MCI and HC (P 0.9 for distinguishing BPSD from non-BPSD patients. 3 key findings →

Participants: 40 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Muti-band Morlet mutual information functional connectivity for classifying Alzheimer's disease and frontotemporal dementia with a deep learning technique

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Computers in Biology and Medicine 2025-09-05

Accurate differentiation of Alzheimer's disease (AD), frontotemporal dementia (FTD), and healthy control (HC) is critical for early diagnosis and intervention of brain disorders. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed